Loading...
Loading...
DMAC| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 4,741.0K |
| Gross Profit | -4,741.0K |
| Operating Expense | 4,741.0K |
| Operating I/L | -4,741.0K |
| Other Income/Expense | 271.0K |
| Interest Income | 0.0K |
| Pretax | -4,470.0K |
| Income Tax Expense | 7.0K |
| Net Income/Loss | -4,477.0K |
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing treatments for neurological and kidney diseases. The company's lead drug candidate, DM199, is in Phase 2 REDUX trial for chronic kidney disease caused by diabetes and Phase 2/3 REMEDY2 trials for acute ischemic stroke. Additionally, DiaMedica is developing DM300 for inflammatory diseases. The company generates revenue through the development and potential commercialization of these drug candidates, aiming to address unmet medical needs in the market.
